The main expected impact of the LAKANA trial is improved infant survival and health, first in the Kayes and Kita regions of Mali and later in the rest of Mali and other West African countries with high infant mortality.
Additional expected positive impacts include:
Improved capacity for medical care in approximately 100 health facilities in Kita and Kayes regions of Mali.
Improved capacity in the Malian national health system for completing mass drug administration and seasonal malaria chemoprevention campaigns.
Improved human and material capacity in Mali for conducting clinical and epidemiological research.
Expanded laboratory capacity in Mali, for antimicrobial resistance monitoring and for other laboratory testing.